Biogen

OverviewSuggest Edit

Biogen is a biopharmaceutical company that discovers, develops, and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases. It is primarily focused on developing medicines to treat multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. The company also manufactures and commercializes biosimilars of advanced biologics.
TypePublic
Founded1978
HQCambridge, MA, USMap
Websitebiogen.com
Employee Ratings4.2More
Overall CultureA+More
View Jobs (267)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)7,400(-5%)
Job Openings267
Revenue (FY, 2020)$13.4 B(-6%)
Share Price (Jun 2021)$286.1(+5%)
Cybersecurity ratingCMore

Key People/Management at Biogen

Michel Vounatsos

Michel Vounatsos

Chief Executive Officer and Director
Stelios Papadopoulos

Stelios Papadopoulos

Chairman of the Board
Susan Alexander

Susan Alexander

Chief Legal Officer and Secretary
Alphonse Galdes

Alphonse Galdes

Head of Pharmaceutical Operations and Technology
Alisha Alaimo

Alisha Alaimo

President, Biogen U.S. Organization
Ginger Gregory

Ginger Gregory

Chief Human Resources Officer
Show more

Biogen Office Locations

Biogen has offices in Cambridge, Morrisville, Waltham, Washington and in 34 other locations
Cambridge, MA, US (HQ)
225 Binney St
Morrisville, NC, US
5000 Davis Dr
Waltham, MA, US
203 Crescent St #303
Washington, DC, US
601 Pennsylvania Ave NW #720
Weston, MA, US
133 Boston Post Rd
Vicente López, AR
7th Floor, Av. del Libertador 350
Show all (39)

Biogen Financials and Metrics

Biogen Revenue

Embed Graph
View revenue for all periods
Biogen's revenue was reported to be $13.44 b in FY, 2020
USD

Revenue (FY, 2020)

13.4b

Gross profit (FY, 2020)

11.6b

Gross profit margin (FY, 2020), %

86.6%

Net income (FY, 2020)

4.1b

EBIT (FY, 2020)

4.6b

Market capitalization (4-Jun-2021)

43.1b

Closing stock price (4-Jun-2021)

286.1

Cash (31-Dec-2020)

1.3b

EV

49.2b
Biogen's current market capitalization is $43.1 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

12.3b13.5b14.4b13.4b

Revenue growth, %

10%7%

Cost of goods sold

1.6b1.8b2.0b1.8b

Gross profit

10.6b11.6b12.4b11.6b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

2.8b3.1b3.1b3.1b3.4b3.4b3.5b3.6b3.6b3.5b3.7b3.4b

Cost of goods sold

384.6m366.2m370.0m446.0m421.0m460.8m602.0m476.3m430.0m454.3m411.1m449.1m

Gross profit

2.4b2.7b2.7b2.7b2.9b3.0b2.9b3.1b3.2b3.1b3.3b2.9b

Gross profit Margin, %

86%88%88%86%87%87%83%87%88%87%89%87%
show all
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

1.6b1.2b2.9b1.3b

Accounts Receivable

1.8b2.0b1.9b1.9b

Inventories

902.7m929.9m804.2m

Current Assets

7.9b7.6b8.4b6.9b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

924.0m1.2b1.5b4.1b1.3b2.4b2.2b1.7b2.3b2.6b2.4b2.2b

Accounts Receivable

1.5b1.6b1.6b1.9b2.0b2.0b2.1b2.0b1.9b2.1b2.1b2.0b

Inventories

921.6m936.5m1.0b890.8m931.7m916.6m770.2m776.7m751.8m858.8m952.7m1.0b

Current Assets

6.9b7.1b7.6b10.2b7.4b8.7b8.9b7.9b8.4b8.0b8.5b7.8b
show all
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

2.7b4.5b5.9b4.1b

Depreciation and Amortization

1.1b1.0b680.6m457.2m

Inventories

(94.5m)(52.1m)(19.2m)(316.3m)

Cash From Operating Activities

4.6b6.2b7.1b4.2b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

747.5m1.6b2.8b1.2b2.1b3.5b1.4b2.9b4.4b1.4b3.0b3.7b

Depreciation and Amortization

512.0m814.6m992.0m168.9m340.4m686.9m121.1m238.1m567.6m119.9m232.8m366.8m

Inventories

(46.2m)(85.3m)(170.3m)(2.6m)(40.1m)(31.9m)(129.0m)(108.7m)(47.3m)(62.2m)(188.2m)(270.6m)

Cash From Operating Activities

235.2m1.4b3.0b1.5b2.6b4.3b1.5b3.4b5.1b1.5b3.4b4.6b
show all
USDQ1, 2017

Debt/Equity

0.6 x

Debt/Assets

0.3 x

Financial Leverage

1.8 x
Show all financial metrics

Biogen Operating Metrics

FY, 2016FY, 2017FY, 2018Q1, 2019Q2, 2019Q3, 2019FY, 2019Q1, 2020Q2, 2020Q3, 2020

Phase I Trials Products

447689991113

Phase I/II Trials Products

1

Phase II Trials Products

1012131312121110109

Phase III Trials Products

2343556666
Show all operating metrics

Biogen Acquisitions / Subsidiaries

Company NameDateDeal Size
Nightstar TherapeuticsMarch 04, 2019$800 m
AliveGenJuly 25, 2018$27.5 m
Karyopharm TherapeuticsJanuary 25, 2018$10 m
Remedy PharmaceuticalsMay 18, 2017$120 m
Convergence PharmaceuticalsFebruary 14, 2014$675 m
StromedixFebruary 14, 2014$75 m
TysabriFebruary 28, 2013
Syntonix PharmaceuticalsJanuary 04, 2007$120 m
FumapharmMay 31, 2006
Conforma TherapeuticsMay 03, 2006$150 m
Show more

Biogen Revenue Breakdown

Embed Graph

Biogen revenue breakdown by business segment: 15.9% from Anti-CD20 Therapeutic Programs, 79.1% from Product Revenues and 4.9% from Other

Human Capital Metrics

Source: www.biogen.com
Embed Graph
Show all human capital metrics

Biogen Cybersecurity Score

Cybersecurity ratingPremium dataset

C

75/100

Learn more about our premium products
SecurityScorecard logo

Biogen Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

Learn more about our premium products
CSRHub logo

Biogen Online and Social Media Presence

Biogen's Trends

Embed Graph

Biogen Company Culture

  • Overall Culture

    A+

    79/100

  • CEO Rating

    A

    75/100

  • Compensation

    A+

    90/100

  • Diversity

    A-

    78/100

Learn more on Comparably

Biogen News and Updates

June 04, 2021

FDA’s Decision On Biogen Alzheimer’s Drug Will Be A Watershed Moment For The Agency — And The Biotech Industry

A controversial drug could be the newest Alzheimer’s treatment in 20 years, but some experts say it won’t work.
June 01, 2021

Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra® (Tocilizumab)

The comparative study met its primary endpoints and showed equivalent efficacy and comparable safety profile in patients with moderate-to-severe rheumatoid arthritis The comparative study met its primary endpoints and showed equivalent efficacy and comparable safety profile in patients with moderate…
May 21, 2021

Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform

CAMBRIDGE, Mass. and BOSTON, May 21, 2021 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Ginkgo Bioworks today announced a gene therapy collaboration. Together, the companies aim to redefine the industry standard for manufacturing recombinant adeno-associated virus (AAV)-based vectors.
May 14, 2021

Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP

CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced topline results from the Phase 2/3 XIRIUS study of cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients with X-linked retinitis pigmentosa (XLRP). XLRP…
May 13, 2021

Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research

CAMBRIDGE, Mass. and NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Envisagenics today announced a new collaboration to advance ribonucleic acid (RNA) splicing research within central nervous system (CNS) diseases. As part of the collaboration, Biogen will leverage Envis…
May 13, 2021

Biogen Hopes Alzheimer’s Drug Mired in Controversy Earns FDA Nod

Biogen Hopes Alzheimer’s Drug Mired in Controversy Earns FDA Nod
Show more

Biogen Blogs

June 16, 2021

Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease

Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease Content Import Wed, 06/16/2021 - 16:30 Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease June 16,…
June 14, 2021

Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia

Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia Content Import Mon, 06/14/2021 - 16:06 Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia June 14, 2021 This release is a backfill from a News Wir…
June 10, 2021

Biogen Announces Investor Day on September 21, 2021

CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Biogen Inc.   (Nasdaq: BIIB) announced today that it will hold an Investor Day focused on its broad pipeline across neuroscience and related therapeutic adjacencies. The event will be webcast live on September 21, 2021 at 10:00 a.m. ET.
June 07, 2021

A Letter from Biogen’s CEO on ADUHELM

Today, on behalf of my Biogen colleagues, I am incredibly humbled to share that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for ADUHELMTM (aducanumab-avwa), the first-ever therapy to address a defining pathology of Alzheimer’s disease—amyloid beta plaque.  We come
June 07, 2021

Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™

Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™ Content Import Mon, 06/07/2021 - 13:01 Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™ June 7, 2021 T…
June 07, 2021

FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease

FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease Content Import Mon, 06/07/2021 - 13:00 FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address…
Show more

 Biogen Frequently Asked Questions

  • When was Biogen founded?

    Biogen was founded in 1978.

  • Who are Biogen key executives?

    Biogen's key executives are Michel Vounatsos, Stelios Papadopoulos and Susan Alexander.

  • How many employees does Biogen have?

    Biogen has 7,400 employees.

  • What is Biogen revenue?

    Latest Biogen annual revenue is $13.4 b.

  • What is Biogen revenue per employee?

    Latest Biogen revenue per employee is $1.8 m.

  • Who are Biogen competitors?

    Competitors of Biogen include Cassava Sciences, Covance and Sanofi Genzyme.

  • Where is Biogen headquarters?

    Biogen headquarters is located at 225 Binney St, Cambridge.

  • Where are Biogen offices?

    Biogen has offices in Cambridge, Morrisville, Waltham, Washington and in 34 other locations.

  • How many offices does Biogen have?

    Biogen has 39 offices.